|Publication number||US6788970 B1|
|Application number||US 10/132,044|
|Publication date||Sep 7, 2004|
|Filing date||Apr 24, 2002|
|Priority date||Apr 5, 2000|
|Also published as||EP1142608A2|
|Publication number||10132044, 132044, US 6788970 B1, US 6788970B1, US-B1-6788970, US6788970 B1, US6788970B1|
|Inventors||Euljoon Park, Alan H. Kadish, Eric Falkenberg|
|Original Assignee||Pacesetter, Inc.|
|Export Citation||BiBTeX, EndNote, RefMan|
|Patent Citations (20), Non-Patent Citations (4), Referenced by (58), Classifications (4), Legal Events (4)|
|External Links: USPTO, USPTO Assignment, Espacenet|
This application is a continuation-in-part of copending U.S. patent application Ser. No. 09/543,832, filed Apr. 5, 2000, titled “System and Method for Prevention of Recurrent Vasovagal Syncope Using Cardiac Pacing.”
The invention generally relates to cardiac pacing techniques and in particular to techniques for treating vasovagal syncope using cardiac pacing.
Syncope is a sudden loss of strength or consciousness caused by reduced cerebral circulation, itself typically the result of vasodilation. Vasovagal syncope is a type of syncope referred to as a neurocardiogenic syncope wherein the syncope is triggered by an interaction between the heart and nerve tissue connected to the heart. Neurocardiogenic syncope may also be referred to as neuromediated syncope, neurally mediated syncope, neurocardiogenic syncope, cardioneurogenic syncope, vasodepressor syncope, malignant vasovagal syndrome, neurally mediated hypotension/bradycardia and cardiovascular neurogenic syncope. For vasovagal syncope, the interaction occurs between the heart and the vagus nerve.
Evidence suggests that vasovagal syncope is initially triggered by a sudden reduction in peripheral vascular resistance, perhaps resulting from stress, pooling of blood in the extremities, or other factors. As a result of the reduction in peripheral vascular resistance, the pressure of blood entering the heart drops and the amount of blood filling the ventricles prior to ventricular contractions therefore also drops. With less blood in the ventricles, the ventricles thereby contract much more quickly and vigorously than would otherwise occur in an effort to maintain a constant stroke volume. The more vigorous ventricular contractions have the effect of stimulating ventricular mechanoreceptors, also known as C fibers, that normally only respond to ventricular expansion or stretching, rather than contraction. The activation of the ventricular mechanoreceptors results in a surge in neural traffic to the brainstem, particularly to the nucleus tractus solitaries, via the vasovagal nerve.
For most people, the neurological system properly interprets the increase of activity of the mechanoreceptors as being in response to a drop in peripheral vascular resistance and compensates by increasing the heart rate and constricting the blood vessels. However, in certain patients, as a result of a neurological condition within the vagus nerve or for some other reason, the surge in neural traffic is falsely perceived by the neurological system as being representative of hypertension. In response thereto, the brainstem triggers an increase in peripheral vasodilation and a reduction in heart rate. The vasodilation and the drop in heart rate, in turn, cause a still further reduction in blood pressure, i.e., hypotension. In other words, the actions taken by the brainstem exacerbate the problem. If the degree of hypotension is sufficiently severe, cerebral hypoperfusion occurs wherein brain cells do not receive enough oxygen and, consequently, the victim loses consciousness. Accordingly, within these patients, any sudden drop in peripheral vascular resistance can trigger vasovagal syncope and the patients then suffer from recurrent vasovagal syncope. Further information regarding vasovagal syncope may be found in S. Serge Barold and Jacques Mugica, Recent Advances in Cardiac Pacing, Futura Publishing Company, 92-95, 1997.
As can be appreciated, loss of consciousness can be particularly dangerous for the patient if occurring while the patient is driving a motor vehicle, climbing a flight of stairs or engaged in any other activity wherein the loss of consciousness could result in injury or death. Accordingly, it is highly desirable to provide techniques for preventing or at least mitigating the symptoms that occur from vasovagal syncope or other forms of neurocardiological syncope.
One possible technique for preventing vasovagal syncope is to employ a pacemaker, or other implantable cardiac pacing device, to pace the heart to prevent the reduction in blood pressure associated with vasovagal syncope from occurring. Indeed, the American College of Cardiology-American Heart Association suggested in 1991 that vasovagal syncope in patients should be used as a Class 2 indication for pacing therapy. However, conventional cardiac pacemakers have had only limited success in preventing recurrent vasovagal syncope. (See David G. Benditt et al., Cardiac Pacing for Prevention of Recurrent Vasovagal Syncope, Ann Intem Med. 1995; 122; 204-209.) Insofar as vasovagal syncope is concerned, conventional pacemakers only respond to the reduction in heart rate associated therewith. The reduction in heart rate, also referred to as bradycardia, is detected by the pacemaker, which increases the heart rate to compensate. Depending upon the programming of the pacemaker, it may take five to eight seconds or more before the pacemaker begins increasing the heart rate in response to detection of bradycardia. For many patients subject to recurrent vasovagal syncope, a significant drop in blood pressure occurs before there is any bradycardia. Hence, by the time the pacemaker begins to increase the heart rate, the blood pressure will already have dropped to the point where the increase in heart rate is ineffective. In this regard, the drop in blood pressure results in significantly less blood filling the ventricles, such that there is simply not enough incoming blood to pump. Hence, overall blood pressure is not significantly increased merely by pumping the heart faster, and the aforementioned cerebral hypoperfusion still occurs resulting in unconsciousness. Moreover, for at least some patients subject to recurrent vasovagal syncope, there is no significant drop in heart rate, only a drop in blood pressure. Hence, pacemakers programmed to prevent vasovagal syncope based solely upon detection of bradycardia will have little or no effect.
Thus, bradycardia-triggered vasovagal syncope prevention techniques employed by some conventional cardiac pacemakers often fail to prevent the syncope. Moreover, conventional cardiac pacemakers are often unable to distinguish physiologic bradycardia such as that associated with sleep from bradycardia associated with vasovagal syncope or other neurocardiogenic syncope.
Accordingly, it would be highly desirable to provide improved cardiac pacing devices capable of predicting the onset of vasovagal syncope or other types of neurocardiogenic syncope, and for reliably administering pacing therapy to prevent the syncope from occurring. It is to these ends that the invention is primarily directed.
In accordance with one aspect of the invention, a cardiac pacing device is provided with a control system that is programmed or configured to execute vasovagal syncope prediction, compensation, and/or prevention algorithms for predicting the onset of vasovagal syncope and for administering pacing therapy to prevent the syncope from occurring or at least mitigate symptoms related to vasovagal syncope. That is, an increase in pacing rate can be used to compensate for the decrease in cardiac output associated vasovagal syncope that occur with pathological changes in vagal tone. Prediction of the onset of vasovagal syncope is based upon an analysis of the contractility of the heart muscle.
In an exemplary embodiment, prediction of the onset of vasovagal syncope is achieved by sensing the contractility of the heart muscle and determining whether the sensed contractility exceeds an average contractility by a predetermined threshold amount. If so, the heart is paced at a “vasovagal syncope prevention rate”, which may be, for example, 20 to 40 beats per minute faster than a previous heart rate. Hereinafter, the term “vasovagal syncope prevention rate” is understood to mean a rate that prevents or mitigates the symptoms related to vasovagal syncope. The term “preventative pacing”, as used herein, is also understood to include preventing or compensating for an episode of vasovagal syncope, including episodes of sudden rate drop and vasodilation that result in poor or sudden decreases in vagal tone, which are compensated by increasing cardiac output with an increase in pacing rate.
In one embodiment, the contractility of the heart is determined, for example, by measuring the electrical impedance change or pressure change in the ventricle, or by measuring the movement of heart tissue in the wall of the heart using an accelerometer. The contractility measured is averaged over a period of time to determine the average contractility.
It is recognized that the contractility of the heart may be determined in a variety of ways, as will be shown below. Since the exact method is not critical to practicing the invention, it is within the spirit of the invention that any method of determining contractility may be employed. However, for convenience and simplicity, it is preferred to employ a technique that does not require a special lead, for example, by measuring the electrical impedance or the rate of change of impedance, ventricular gradient or post-depolarization integral, QT interval, heart sounds, etc. Specially-made leads that incorporate sensors, of course, may also be used, for example, leads that measure pressure change in the ventricle, or by measuring the movement of heart tissue in the wall of the heart using an accelerometer. In any case, the contractility measured is averaged over a period of time to determine the average contractility.
In this manner, the onset of vasovagal syncope is predicted based upon changes in heart muscle contractility and syncope is substantially prevented from occurring, or at least the symptoms are mitigated, by immediately administering vasovagal syncope preventative pacing measures. Because prediction of imminent vasovagal syncope is based upon a measurement of the contractility of the heart tissue, rather than upon detection of an episode of bradycardia, vasovagal syncope is thereby detected even in circumstances wherein hypotension occurs before bradycardia or wherein bradycardia does not occur at all. Also, physiologic episodes of bradycardia, such as those associated with sleep, do not erroneously trigger the vasovagal syncope pacing therapy. Moreover, the increase in contractility associated with vasovagal syncope can be detected quickly whereas reliable bradycardia detection may require analysis of several heart beats. Hence, preventative pacing may be administered before the blood pressure has dropped significantly, as could otherwise occur if relying solely on bradycardia detection. Two or more independent contractility sensors may be provided to help prevent a false positive detection of vasovagal syncope.
Method embodiments of the invention are also provided. Other features, advantages and aspects of the invention are either described below or will be apparent from the descriptions below in combination with the accompanying drawings.
Further features and advantages of the invention may be more readily understood by reference to the following description taken in conjunction with the accompanying drawings, in which:
FIG. 1 is a functional block diagram of a dual-chamber implantable stimulation device illustrating the basic elements of a stimulation device which can provide cardioversion, defibrillation and pacing stimulation and can predict and prevent vasovagal syncope in accordance with an exemplary embodiment of the invention;
FIG. 2 is a graph illustrating a vasovagal syncope preventative pacing regime;
FIG. 3 is a flow chart illustrating steps performed by the pacemaker components of FIG. 2; and
FIGS. 4-5 illustrate a detailed flow chart describing the steps performed by a pacemaker configured to pace the heart using a sensor indicated rate (SIR) and also configured to perform vasovagal syncope preventative pacing.
The following description is of the best mode presently contemplated for practicing the invention. This description is not to be taken in a limiting sense but is made merely for the purpose of describing the general principles of the invention. The scope of the invention should be ascertained with reference to the issued claims. In the description of the invention that follows, like numerals or reference designators will be used to refer to like parts or elements throughout.
In FIG. 1, a simplified block diagram is shown of a dual-chamber implantable stimulation device 10 which is capable of treating both fast and slow arrhythmias with stimulation therapy, including cardioversion, defibrillation, and pacing stimulation. While a dual-chamber device is shown, this is for illustration purposes only, and one of skill in the art could readily eliminate, add or disable the appropriate circuitry to provide a single-chamber or a four-chamber stimulation device capable of treating one chamber with cardioversion, defibrillation and pacing stimulation. For a complete description of an implantable stimulation device capable of pacing and sensing in up to four chambers of the heart arid/or providing shock therapy, see U.S. application Ser. No. 09/930,725, entitled “Multi-site cardiac stimulation device for controlling Interchamber Delay” (Richard Lu) filed Aug. 14, 2001, which application is incorporated herein by reference.
To provide atrial chamber pacing stimulation and sensing, the stimulation device 10 is shown in electrical communication with a patient's heart 12 by way of an implantable atrial lead 20 having an atrial tip electrode 22 and an atrial ring electrode 24 which typically is implanted in the patient's atrial appendage.
The stimulation device 10 is also shown in electrical communication with the patient's heart 12 by way of an implantable ventricular lead 30 having, in this embodiment, a ventricular tip electrode 32, a ventricular ring electrode 34, a right ventricular (RV) coil electrode 36, and an SVC coil electrode 38. Typically, the ventricular lead 30 is transvenously inserted into the heart 12 so as to place the RV coil electrode 36 in the right ventricular apex, and the SVC coil electrode 38 in the superior vena cava. Accordingly, the ventricular lead 30 is capable of receiving cardiac signals, and delivering stimulation in the form of pacing and shock therapy to the right ventricle.
While only two leads are shown in FIG. 1, it is to be understood that additional stimulation leads (with one or more pacing, sensing and/or shocking electrodes) may be used in order to efficiently and effectively provide pacing stimulation to the left side of the heart or atrial cardioversion and/or defibrillation. For example, a lead designed for placement in the coronary sinus region could be implanted to deliver left atrial pacing, atrial shocking therapy, and/or for left ventricular pacing stimulation. For a complete description of a coronary sinus lead, see U.S. patent application Ser. No. 09/457,277, filed Dec. 8, 1999, which is a continuation-in-part of U.S. patent application Ser. No. 09/196,898, “A Self-Anchoring Coronary Sinus Lead” (Pianca et al.), filed Nov. 20, 1998 (abandoned); and U.S. Pat. No. 5,466,254, “Coronary Sinus Lead with Atrial Sensing Capability” (Helland), which patents are hereby incorporated herein by reference.
The housing 40 (shown schematically) for the stimulation device 10 includes a connector (not shown) having an atrial pin terminal 42 and an atrial ring terminal 44, which are adapted for connection to the atrial tip electrode 22 and the atrial ring electrode 24, respectively. The housing 40 further includes a ventricular pin terminal 52, a ventricular ring terminal 54, a ventricular shocking terminal 56, and an SVC shocking terminal 58, which are adapted for connection to the ventricular tip electrode 32, the ventricular ring electrode 34, the RV coil electrode 36, and the SVC coil electrode 38, respectively. The housing 40 (often referred to as the “can”, “case” or “case electrode”) may be programmably selected to act as the return electrode, or anode, alone or in combination with one of the coil electrodes, 36 and 38. For convenience, the names of the electrodes are shown next to the terminals.
At the core of the stimulation device 10 is a programmable microcontroller 60 which controls the various modes of stimulation therapy. As is well known in the art, the microcontroller 60 includes a microprocessor, or equivalent control circuitry, designed specifically for controlling the delivery of stimulation therapy and may further include RAM or ROM memory, logic and timing circuitry, state machine circuitry, and I/O circuitry. Typically, the microcontroller 60 includes the ability to process or monitor input signals (data) as controlled by a program code stored in a designated block of memory. The details of the design and operation of the microcontroller 60 are not critical to the present invention. Rather, any suitable microcontroller 60 may be used that carries out the functions described herein. The use of microprocessor-based control circuits for performing timing and data analysis functions is well known in the art as shown in FIG. 1, an atrial pulse generator 70 and a ventricular pulse generator 72 generate pacing stimulation pulses for delivery by the atrial lead 20 and the ventricular lead 30, respectively, via a switch bank 74. The pulse generators, 70 and 72, are controlled by the microcontroller 60 via appropriate control signals, 76 and 78, respectively, to trigger or inhibit the simulation pulses. The microcontroller 60 further includes timing circuitry that controls the operation of the stimulation device timing of such stimulation pulses that is well known in the art.
The switch bank 74 includes a plurality of switches for switchably connecting the desired electrodes to the appropriate I/O circuits, thereby providing complete electrode programmability. Accordingly, the switch bank 74, in response to a control signal 80 from the microcontroller 60, determines the polarity of the stimulation pulses (e.g., unipolar or bipolar) by selectively closing the appropriate combination of switches (not shown) as is known in the art. An atrial sense amplifier 82 and a ventricular sense amplifier 84 are also coupled to the atrial and ventricular leads 20 and 30, respectively, through the switch bank 74 for detecting the presence of cardiac activity. The switch bank 74 determines the “sensing polarity” of the cardiac signal by selectively closing the appropriate switches, as is also known in the art. In this way, the clinician may program the sensing polarity independent of the stimulation polarity.
Each sense amplifier, 82 and 84, preferably employs a low power, precision amplifier with programmable gain and/or automatic gain control, bandpass filtering, and a threshold detection circuit, known in the art, to selectively sense the cardiac signal of interest. The automatic gain control enables the device 10 to deal effectively with the difficult problem of sensing the low frequency, low amplitude signal characteristics of ventricular fibrillation.
The outputs of the atrial and ventricular sense amplifiers, 82 and 84, are connected to the microcontroller 60, which, in turn, inhibit the atrial and ventricular pulse generators, 70 and 72, respectively, in a demand fashion whenever cardiac activity is sensed in the respective chambers.
For arrhythmia detection, the present device utilizes the atrial and ventricular sense amplifiers, 82 and 84, to sense cardiac signals to determine whether a rhythm is physiologic or pathologic. As used herein “sensing” is reserved for the noting of an electrical depolarization, and “detection” is the processing of these sensed depolarization signals and noting the presence of an arrhythmia. The timing intervals between sensed events (e.g., the P-P and R-R intervals) are then classified by the microcontroller 60 by comparing them to a predefined rate zone limit (i.e., bradycardia, normal, low rate VT, high rate VT, and fibrillation rate zones) and various other characteristics (e.g., sudden onset, stability, physiologic sensors, and morphology, etc.) in order to determine the type of remedial therapy that is needed (e.g., bradycardia pacing, anti-tachycardia pacing, cardioversion shocks or defibrillation shocks, also known as “tiered therapy”).
Cardiac signals are also applied to the inputs of an analog to digital (AID) data acquisition system 90. The data acquisition system 90 is configured to acquire intracardiac electrogram signals, convert the raw analog data into a digital signal, and store the digital signals for later processing and/or telemetric transmission to an external device 102. The data acquisition system 90 is coupled to the atrial and ventricular leads, 20 and 30, through the switch bank 74 to sample cardiac signals across any pair of desired electrodes.
The microcontroller 60 is further coupled to a memory 94 by a suitable data/address bus 96, wherein the programmable operating parameters used by the microcontroller 60 are stored and modified, as required, in order to customize the operation of the stimulation device 10 to suit the needs of a particular patent. Such operating parameters define, for example, pacing pulse amplitude, pulse duration, electrode polarity, rate, sensitivity, automatic features, arrhythmia detection criteria, and the amplitude, waveshape and vector of each shocking pulse to be delivered to the patient's heart 28 within each respective tier of therapy.
Advantageously, the operating parameters of the implantable device 10 may be non-invasively programmed into the memory 94 through a telemetry circuit 100 in telemetric communication with an external device 102, such as a programmer, transtelephonic transceiver, or a diagnostic system analyzer. The telemetry circuit 100 is activated by the microcontroller by a control signal 106. The telemetry circuit 100 advantageously allows intracardiac electrograms and status information relating to the operation of the device 10 (as contained in the microcontroller 60 or memory 94) to be sent to the external device 102 through the established communication link 104.
In the preferred embodiment, the stimulation device 10 further includes a physiologic sensor 110. Such sensors are commonly called “rate-responsive” sensors. The physiological sensor 110 is used to detect the exercise state of the patient, to which the microcontroller 60 responds by adjusting the rate and AV Delay at which the atrial and ventricular pulse generators, 70 and 72, generate stimulation pulses. The type of sensor used is not critical to the present invention and is shown only for completeness.
The stimulation device additionally includes a battery 114 which provides operating power to all of the circuits shown in FIG. 1. For the stimulation device 10, which employs shocking therapy, the battery must be capable of operating at low current drains for long periods of time, and then be capable of providing high-current pulses (for capacitor charging) when the patient requires a shock pulse. The battery 114 must also have a predictable discharge characteristic so that elective replacement time can be detected. Accordingly, the device employs lithium/silver vanadium oxide batteries, as is true for most (if not all) such devices to date.
It is the primary function of the invention to function as an implantable cardioverter/defibrillator (ICD) device. That is, it must detect the occurrence of an arrhythmia, and automatically apply an appropriate electrical shock therapy to the heart aimed at terminating the detected arrhythmia. To this end, the microcontroller 60 further controls a shocking circuit 130 by way of a control signal 132. The shocking circuit 130 generates shocking pulses of low (up to 0.5 Joules), moderate (0.5-10 Joules), or high energy (11 to 40 Joules), as controlled by the microcontroller 60. Such shocking pulses are applied to the patient's heart through at least two shocking electrodes, and as shown in this embodiment, using the RV and SVC coil electrodes, 36 and 38, respectively. In alternative embodiments, the housing 40 may act as an active electrode in combination with the RV electrode 36 alone, or as part of a split electrical vector using the SVC coil electrode 38 (i.e., using the RV electrode as common).
Cardioversion shocks are generally considered to be of low to moderate energy level (so as to minimize pain felt by the patient), and/or synchronized with an R-wave and/or pertaining to the treatment of tachycardia. Defibrillation shocks are generally of moderate to high energy level (i.e., corresponding to thresholds in the range of 5-40 Joules), delivered asychronously (since R-waves may be too disorganized), and pertaining exclusively to the treatment of fibrillation. Accordingly, the microcontroller 60 is capable of controlling the synchronous or asynchronous delivery of the shocking pulses.
The present invention utilizes a desired “inotropic sensor” that provides or corresponds to a measure of the instantaneous contractility of the patient's heart.
In one embodiment, the ventricular lead 30 includes at least one contractility sensor 121, e.g., an accelerometer, a pressure sensor, and/or an impedance sensor (hereinafter referred to as the “contractility sensor(s) 121”).
Device 10 is configured to sense the contractility of the heart using the contractility sensor(s) 121 on ventricular lead 20 and, in response to a sudden increase in the contractility of the heart, to immediately pace the heart at an elevated rate to prevent vasovagal syncope from occurring, or to delay the progression of vasovagal syncope. To this end, device 10 includes signal conditioning circuitry 120 or other input circuit which receives analog signals via one or more terminals 123 and 124 from the contractility sensor(s) (shown schematically in dotted lines) and converts the analog sign into digital signals from processing by controller 60.
The controller 60 includes software for analyzing the signals received from the signal conditioning circuitry 120 to determine the contractility of the heart.
For example, in one embodiment, the controller 60 analyzes the signals to first estimate the amount of blood within the right ventricle. Based upon the estimate of the amount of blood in the right ventricle, controller 60 further then estimates the contractility of the muscles of the right ventricle.
The controller also determines the average contractility and stores it in memory 94 or within a separate contractility storage register (not shown). Controller 60 then compares the sensed contractility of the heart with the average contractility of the heart and controls atrial and ventricular pulse generators 70 and 72 to administer pacing pulses to the heart at an accelerated rate in an effort to compensate for the reduction in blood pressure otherwise occurring prior to vasovagal syncope.
In another embodiment, the data acquisition system 90 may acquire the intracardiac electrogram through the pacing/sensing electrodes (e.g., ventricular electrodes 32, 34 and/or atrial electrode 22, 24) or by a sensor in the housing itself, so that the signal conditioning circuit 120 can determine the patients current contractility based on, for example, the ventricular gradient, impedance, heart sounds, PEP, etc. Hereinafter the “inotropic” or “contractility” sensor, whether using a sensor on the lead (illustrated at element 121, e.g., a sensor near the ring electrode), the intracardiac electrogram, or a sensor in the housing, shall be referred to herein generally as the “contractility sensor(s) 121”, since at least one, and/or more than one can be used. The processing of the contractility sensor may occur in hardware using the signal conditioning circuit 120, or using the A/D data acquisition system 90 and software in the microcontroller 60, such as, a contractility processing algorithm 125.
As noted, controller 60 may determine contractility based on pressure, acceleration or pressure signals, or a combination thereof, received from the contractility sensor(s).
Other “inotropic” sensors that can measure contractility are numerous and well known in the art.
For example, contractility may be measured using pressure waves, for example, in U.S. Pat. No. 6,208,900 (Ecker et al.) and U.S. Pat. No. 4,485,813 (Anderson et al.), which patents are hereby incorporated herein by reference.
Heart sound waves can be used to determine contractility and other related parameters (e.g., stroke volume, blood pressure and dP/dt), as disclosed in U.S. Pat. No. 6,044,299 (Nilsson), which is hereby incorporated herein by reference.
Intracardiac electrogram signals may also be basis for determining contractility, e.g., using the intracardiac electrogram to derive a “ventricular gradient” and QT interval. “Ventricular gradient”, also sometimes referred to as “paced depolarization integral”, is the integral of the paced R-wave (or P-wave) signal and is also believed to correlate to contraction force. See, for example, U.S. Pat. No. 4,759,366 (Callaghan). It is further believed that the atrial contractility may be used to enhance or augment the vasovagal algorithm. The QT interval, that is the interval between a delivered ventricular stimulus and an evoked T-wave, is also based entirely on the detection of the evoked cardiac signal, as disclosed in U.S. Pat. No. 4,527,568. Both the '366 and the '568 patents are hereby incorporated herein by reference.
Combination of sensors may also be employed. For example, pre-ejection period (PEP), as taught in U.S. Pat. No. 4,719,921 (Chirife), is the sensing of the elapsed time from the ventricular depolarization corresponding to the QRS complex and the onset of ventricular ejection, which can be measured using the electrogram signal and a blood flow sensor, impedance sensor, or a ventricular volume detector, etc. The '921 patent is also hereby incorporated herein by reference.
Impedance measurements of blood in the heart have also been employed to derive contractility of the myocardium, and stroke volume in U.S. Pat. No. 4,884,576 (Alt) and U.S. Pat. No. 4,535,774 (Olsen). Also, the rate of change in impedance (dZ/dt) has been shown to correspond to contractility, see, for example, U.S. Pat. No. 4,733,667 (Olive et al.) and U.S. Pat. No. 5,800,467 (Park et al.), the disclosures of which are hereby expressly incorporated herein by reference.
For example, one technique for estimating contractility based upon electrical impedance detected within the heart is described within U.S. Pat. No. 5,800,467 to Park et al., entitled “Cardio-Synchronous Impedance Measurement System for an Implantable Stimulation Device,” which is incorporated by reference herein. Briefly, blood is an electrical conductor and, hence, a decrease in the amount of blood in the ventricle results in an increase in electrical impedance. Impedance therefore, as measured within the ventricle of the heart, provides an indication of the amount of blood in the ventricle. Controller 60 monitors the impedance of the heart and detects any sharp increase in the impedance from one cycle to the next. The increase in impedance is therefore interpreted as a decrease in the amount of blood filling the ventricle during the cardiac cycle. As noted above, a sudden drop in ventricular filling causes the ventricle to contract more vigorously, i.e. the contractility of the ventricle increases. The sharp increase in contractility causes mechano-receptors within the ventricle to transmit signals to the vagus nerve, which are forwarded to the brainstem. For patients with recurrent vasovagal syncope, the resulting surge in signals is misinterpreted as being representative of hypertension and the brainstem dilates blood vessels and decreases the heart rate in an attempt to compensate for the hypertension. This results in a significant drop in blood pressure causing hypoperfusion of the cerebrum and possibly loss of consciousness. Hence, a sharp increase in impedance from one period of ventricular contraction to the next is a good indicator of the potential onset of vasovagal syncope, at least within patients who suffer from recurrent vasovagal syncope. Accordingly, the '576, '774, '667 and '467 patents are all hereby incorporated herein by reference.
Cardiac wall motion sensors enable the use of cardiac wall acceleration signal (wall motion), velocity (force of contraction/contractility) and displacement (stroke volume), and can further be processed to determine pre-ejection intervals, ejection time, and maximum rate of change of ventricular volume. Thus, one technique for estimating contractility based upon signals from an accelerometer within the right ventricle is as follows. The accelerometer generates signals representative of the speed at which the ventricular wall moves during a contraction. The increase in contractility caused by a sudden drop in ventricular filling results in the ventricular walls moving more forcefully. Hence, by monitoring the signals received from the accelerometer, controller 60 is able to estimate the contractility of the ventricle.
One specific technique for measuring heart contractility using an accelerometer is described within U.S. Pat. No. 5,480,412 to Mouchawar et al., entitled “System and Method for Deriving Hemodynamic Signals from a Cardiac Wall Motion Sensor,” which is incorporated by reference herein.
Another technique for measuring heart contractility using an impedance sensor is described within U.S. Pat. No. 5,139,020 to Koestner, et al., entitled “Method and Apparatus for Controlling the Hemodynamic State of a Patient Based on Systolic Time Interval Measurements Detecting Using Doppler Ultrasound Techniques,” which is incorporated by reference herein.
While the above patents demonstrate the existence of contractility sensors available, they are presented for illustration purposes and should not be considered a comprehensive list. The type of contractility sensor is not critical to the invention, and any sensor that provides an indicator of the strength of the contraction is considered within the scope of the invention.
Thus, controller 60 tracks the average and current contractility of the heart. The average contractility, stored within memory 94, is determined, for example, by averaging the measured contractility over relatively long periods of time such as minutes, hours, days, weeks, months or years. Controller 60 periodically compares the measured contractility with the average contractility and detects any sharp increase in contractility from one cardiac cycle to the next. As noted above, a sharp increase in contractility from one period to the next is indicative of the onset of vasovagal syncope, at least within patients subject to recurrent vasovagal syncope syndrome. If a sharp increase in contractility is detected, the controller promptly controls atrial and ventricular pulse generators 70 and 72 to increases the heart rate to compensate for the drop in blood pressure that initially triggered the increase in contractility.
In FIG. 3, a flow chart is shown describing an overview of the operation of the novel features of the present invention. In this flow chart, and the other flow charts described herein, the various algorithmic steps are summarized in individual “blocks”. Such blocks describe specific actions or decisions made or carried out as the algorithm proceeds. Where a microcontroller (or equivalent) is employed, the flow charts presented herein provide the basis for a “control program” that may be used by such a microcontroller (or equivalent) to effectuate the desired control of the stimulation device. Those skilled in the art may readily write such a control program based on the flow charts and other descriptions presented herein.
FIG. 2 illustrates a pacing regime which may be employed by controller 60 of FIG. 1 for prevention of vasovagal syncope. Upon detection of the sharp increase in contractility from one cardiac cycle to the next, the pacing rate is immediately increased from an initial pacing rate, PR1, (which may be a programmed base rate such as 60 bpm) to a syncope prevention rate, PR2 (which may be a programmable value, for example, 20, 30 or 40 bpm above the initial pacing rate, PR1). The increase from initial pacing rate, PR1, to syncope prevention rate, PR2, could be a linear increase performed during time T1 which may be, for example, in the range of three to five seconds. The heart is then continuously paced at syncope prevention rate, PR2, for time T2 which may be, for example, in the range of 30 seconds to 3 minutes (e.g., a predetermined or programmable interval). Then, the pacing rate is reduced from syncope prevention rate, PR2, to initial pacing rate, PR1, during T3, wherein T3 is, for example, in the range of 10 to 30 seconds (e.g., a predetermined or programmable interval).
In the alternative, each individual time value T1, T2 and T3 is not separately programmable. Rather, the overall time period T4 is programmed, and the pacemaker automatically calculates the subportions T1, T2 and T3 in accordance with prestored timing ratios. For ease of implementation T1, T2, T3 and T4 could be replaced with the number of the corresponding beats.
In yet another embodiment, the syncope prevention rate, PR2, and time T2 may be determined based on a measured contractility signal in the “normal” range, near the long-term average, for the patient. Contractility has been used in rate responsive pacemakers in a closed-loop fashion. See for example, U.S. Pat. No. 4,759,366 (Callaghan), which has already been incorporated herein by reference above. It is believed that contractility can likewise be used in a closed-loop fashion for vasovagal preventataive pacing.
By increasing the heart rate to syncope prevention rate, PR2, the drop in blood pressure that would otherwise occur during the onset of vasovagal syncope syndrome is at least partially compensated. Although the increase in the heart rate may not be sufficient to prevent the blood pressure from dropping to the point where the patient feels lightheaded or dizzy, it is typically sufficient to prevent the blood pressure from dropping to the point wherein the patient becomes unconscious. Even if the patient ultimately becomes unconscious, the loss of consciousness is delayed by at least some amount permitting the patient to take whatever action is necessary to ensure his or her safety. For example, if the patient is driving a vehicle, the patient, upon becoming lightheaded and dizzy, will preferably pull the vehicle to the side of the road. Thus, even if the patient loses consciousness, the delay in loss of consciousness may be sufficient to save the patient from injury.
By triggering the increase in pacing rate based upon a contractility measurement, the increase is triggered much more promptly than typically occurs within pacemakers configured to detect the onset of vasovagal syncope based upon bradycardia. As noted above, by the time a pacemaker has detected bradycardia, the blood pressure of the patient may already have dropped to the point where a subsequent increase in the heart rate is ineffective for preventing immediate loss of consciousness. By triggering the increase in heart rate based upon a sharp change in contractility, the increase is typically triggered within one or two beats subsequent to the initial drop in blood pressure, which marks the onset of vasovagal syncope. By significantly increasing the heart rate before the blood pressure has a chance to drop significantly, the pacemaker thereby either prevents any drop in blood pressure or, at the very least, defers the drop in blood pressure thereby delaying or preventing unconsciousness.
The steps performed by the components of FIG. 1 for vasovagal detection and prevention are summarized in FIG. 3. Briefly, at step 200, device 10 inputs or otherwise receives a signal from the contractility sensor 121 (e.g., the electrical impedance signals, pressure, accelerometer signals, ventricular gradient (PDI), PEP, heart sounds, etc.).
At step 202, device 10 determines the contractility and, at step 204, compares the detected contractility with the average contractility (e.g. a running average over at least the previous minutes, hours, day, etc.). If, at step 205, the contractility increases to the point where the detected contractility minus the average contractility exceeds a predetermined threshold, then step 206 is performed wherein the device 10 immediately increases the pacing rate to the vasovagal syncope preventative pacing mode using the pacing rate defined in FIG. 2. Otherwise, processing returns to step 200 wherein device 10 continues to monitor the contractility sensor 121 (e.g. the input impedance, pressure, accelerometer signals ventricular gradient (PDI), PEP, heart sounds, etc.). Vasovagal syncope preventative pacing mode performed at step 206 is administered, as described in connection with FIG. 2, for example, for about 30 seconds to 3 minutes. Then, the heart rate is reduced to a base pacing rate or pacing is eliminated completely. Ultimately, processing returns to step 100 to monitor impedance, accelerometer signals and/or pressure.
Thus, FIG. 3 illustrates, at a high level, steps performed to predict and prevent vasovagal syncope using device 10. As described above, device 10 additionally performs numerous other functions simultaneously, such as monitoring the heart to detect heart arrhythmias, such as atrial tachycardia. If a significant heart arrhythmia is detected while the pacemaker is administering the vasovagal syncope preventative pacing mode, the preventative pacing is terminated and the pacemaker administers whatever therapy is appropriate for the arrhythmia. The therapy may include the administration of defibrillation pulses or the like.
FIGS. 4 and 5 illustrate a sequence of steps performed to provide vasovagal preventative pacing within device 10 if the device is configured to pace at a sensor indicated rate (SIR). SIR pacing is described in further detail in U.S. Pat. No. 5,476,483 to Bornzin et al., entitled “System and Method for Modulating the Base Rate During Sleep for a Rate-Responsive Cardiac Pacemaker,” which is incorporated by reference herein.
The sequence of steps illustrated in FIGS. 4 and 5 are generally in accordance with the techniques described above. Hence, the sequence of steps of FIGS. 4 and 5 will not be described in detail but merely summarized herein. Steps 300, 302, 304, 314, 320, 322 and 312 are steps performed by device 10 in response to the initial detection of a sharp increase in contractility wherein the vasovagal preventative pacing mode is initiated. Here, the patient is paced at either the vasovagal preventative pacing rate (VPPR) illustrated in FIG. 2 or a predetermined SIR, whichever is greater. If a further increase in contractility is detected while the patient is already within the vasovagal preventative pacing mode, the pacemaker continues to pace at either SIR or VPPR, whichever is greater. This is illustrated by steps 300, 302, 304, 314, 316, 322 and 312. Note that the vasovagal preventative pacing mode will be reinitiated so long as the contractility remains far above the average contractility level (step 304), i.e., the detected contractility minus the average contractility exceeds the predetermined threshold. In this regard, if the period for vasovagal preventative pacing has completed (step 216), VPPR pacing is suspended only as long as needed to detect that the contractility is still high and, during a subsequent execution of the steps of FIG. 4, VPPR pacing is again triggered.
Once contractility has dropped to an acceptable level, the pacemaker takes the patient out of the vasovagal preventative pacing mode. This is provided by steps 300, 302, 304, 306, 316, 308, 310 and 312 and also by steps 300, 302, 304, 306, 316, 308, 318 and 312.
What have been described are techniques for predicting and preventing vasovagal syncope within patients subject to recurrent vasovagal syncope using an implanted cardiac pacing device. Principles of the invention are applicable to predicting and preventing other types of syncope as well such as other types of neurocardiogenic syncope. Other physiological sensors that reflect the contractility change of the heart can be employed, such as ventricular gradient (also known as paced depolarization interval (PDI); pre-ejection period (PEP), etc.). The techniques are also applicable for use with other implantable medical devices, such as ICDs or the like. Thus, the specific examples herein are be illustrative of the invention and should not be g the scope of the invention.
|Cited Patent||Filing date||Publication date||Applicant||Title|
|US4485813||Nov 19, 1981||Dec 4, 1984||Medtronic, Inc.||Implantable dynamic pressure transducer system|
|US4527568||Dec 27, 1983||Jul 9, 1985||Vitafin N.V.||Dual chamber pacer with alternative rate adaptive means and method|
|US4535774||Jun 30, 1983||Aug 20, 1985||Medtronic, Inc.||Stroke volume controlled pacer|
|US4719921||Aug 28, 1985||Jan 19, 1988||Raul Chirife||Cardiac pacemaker adaptive to physiological requirements|
|US4733667||Aug 11, 1986||Mar 29, 1988||Cardiac Pacemakers, Inc.||Closed loop control of cardiac stimulator utilizing rate of change of impedance|
|US4759366||Mar 19, 1986||Jul 26, 1988||Telectronics N.V.||Rate responsive pacing using the ventricular gradient|
|US4884576||Sep 28, 1988||Dec 5, 1989||Eckhard Alt||Self adjusting rate responsive cardiac pacemaker and method|
|US5139020||Mar 8, 1991||Aug 18, 1992||Telectronics Pacing Systems, Inc.||Method and apparatus for controlling the hemodynamic state of a patient based on systolic time interval measurements detecting using doppler ultrasound techniques|
|US5466254||Sep 22, 1993||Nov 14, 1995||Pacesetter, Inc.||Coronary sinus lead with atrial sensing capability|
|US5476483||Jun 10, 1994||Dec 19, 1995||Pacesetter, Inc.||System and method for modulating the base rate during sleep for a rate-responsive cardiac pacemaker|
|US5480412||Nov 16, 1993||Jan 2, 1996||Pacesetter, Inc.||System and method for deriving hemodynamic signals from a cardiac wall motion sensor|
|US5800467||Dec 13, 1996||Sep 1, 1998||Pacesetter, Inc.||Cardio-synchronous impedance measurement system for an implantable stimulation device|
|US5919210 *||Apr 10, 1997||Jul 6, 1999||Pharmatarget, Inc.||Device and method for detection and treatment of syncope|
|US6044299||Sep 19, 1997||Mar 28, 2000||Pacesetter Ab||Implantable medical device having an accelerometer|
|US6049735 *||Mar 1, 1999||Apr 11, 2000||Cardiac Pacemakers Inc.||Cardiac rhythm management device with detection and therapy for sudden syncopal events|
|US6078834 *||Feb 25, 1999||Jun 20, 2000||Pharmatarget, Inc.||Device and method for detection and treatment of syncope|
|US6208900||Mar 28, 1996||Mar 27, 2001||Medtronic, Inc.||Method and apparatus for rate-responsive cardiac pacing using header mounted pressure wave transducer|
|US20020004670||May 3, 2001||Jan 10, 2002||Florio Joseph J.||Implantable cardiac stimulation device with detection and therapy for patients with vasovagal syncope|
|US20020004672||May 3, 2001||Jan 10, 2002||Florio Joseph J.||Implantable cardiac stimulation device with detection and therapy for patients with vasovagal syncope|
|EP1142608A2||Jan 29, 2001||Oct 10, 2001||Pacesetter, Inc.||System and method for prevention of recurrent vasovagal syncope using cardiac pacing|
|1||Barold, S. Serge et al., Recent Advances in Cardiac Pacing: Goals for the 21<st >Century, 92-95, Futura Publishing Company (1997).|
|2||Barold, S. Serge et al., Recent Advances in Cardiac Pacing: Goals for the 21st Century, 92-95, Futura Publishing Company (1997).|
|3||Benditt; David G. et al., "Cardiac Pacing for Prevention of Recurrent Vasovagal Syncope," 204-209, Ann Intern Med. vol. 122, No. 3 (1995).|
|4||Deharo, J.C. et al., "Treatment of Malignant Primary Basodepressive Neurocardiogenic Syncope with a Rate Responsive Pacemaker Driven by Heart Contractility," 2688-2690, PACE vol. 21 (1998).|
|Citing Patent||Filing date||Publication date||Applicant||Title|
|US7409241 *||Nov 22, 2004||Aug 5, 2008||Ela Medical S.A.S.||Monitoring the sympathico-vagal activity by analysis of endocardiac acceleration in an active implantable medical device|
|US7460906||Dec 24, 2003||Dec 2, 2008||Cardiac Pacemakers, Inc.||Baroreflex stimulation to treat acute myocardial infarction|
|US7509166||Dec 24, 2003||Mar 24, 2009||Cardiac Pacemakers, Inc.||Automatic baroreflex modulation responsive to adverse event|
|US7519422 *||Apr 12, 2005||Apr 14, 2009||Biotronik Crm Patent Ag||Electrotherapy device|
|US7616990||Oct 24, 2005||Nov 10, 2009||Cardiac Pacemakers, Inc.||Implantable and rechargeable neural stimulator|
|US7647114||Sep 13, 2004||Jan 12, 2010||Cardiac Pacemakers, Inc.||Baroreflex modulation based on monitored cardiovascular parameter|
|US7657310||Jan 26, 2006||Feb 2, 2010||Cyberonics, Inc.||Treatment of reproductive endocrine disorders by vagus nerve stimulation|
|US7657312||Nov 3, 2003||Feb 2, 2010||Cardiac Pacemakers, Inc.||Multi-site ventricular pacing therapy with parasympathetic stimulation|
|US7662103 *||Feb 16, 2010||Ela Medical S.A.S.||Apparatus for non-invasive diagnosis of vasovagal syncope in a patient|
|US7706874||Jul 28, 2005||Apr 27, 2010||Cyberonics, Inc.||Stimulating cranial nerve to treat disorders associated with the thyroid gland|
|US7706875||Jan 25, 2007||Apr 27, 2010||Cyberonics, Inc.||Modulation of drug effects by vagus nerve stimulation|
|US7706884||Dec 24, 2003||Apr 27, 2010||Cardiac Pacemakers, Inc.||Baroreflex stimulation synchronized to circadian rhythm|
|US7769436||Jun 4, 2007||Aug 3, 2010||Pacesetter, Inc.||System and method for adaptively adjusting cardiac ischemia detection thresholds and other detection thresholds used by an implantable medical device|
|US7780606||Mar 29, 2006||Aug 24, 2010||Cardiac Pacemakers, Inc.||Hemodynamic stability assessment based on heart sounds|
|US7856273||Jul 28, 2005||Dec 21, 2010||Cyberonics, Inc.||Autonomic nerve stimulation to treat a gastrointestinal disorder|
|US7904175||Apr 26, 2007||Mar 8, 2011||Cyberonics, Inc.||Trans-esophageal vagus nerve stimulation|
|US7938781||Jun 10, 2010||May 10, 2011||Cardiac Pacemakers, Inc.||Hemodynamic stability assessment based on heart sounds|
|US7962214||Jul 27, 2007||Jun 14, 2011||Cyberonics, Inc.||Non-surgical device and methods for trans-esophageal vagus nerve stimulation|
|US7979141||Sep 22, 2009||Jul 12, 2011||Cardiac Pacemakers, Inc.||Transvascular reshaping lead system|
|US8024050||Dec 24, 2003||Sep 20, 2011||Cardiac Pacemakers, Inc.||Lead for stimulating the baroreceptors in the pulmonary artery|
|US8034000||Jul 28, 2009||Oct 11, 2011||Cardiac Pacemakers, Inc.||Ischemia detection using a heart sound sensor|
|US8050759 *||Jan 31, 2006||Nov 1, 2011||Medtronic, Inc.||Subcutaneous ICD with separate cardiac rhythm sensor|
|US8070686||Jul 2, 2007||Dec 6, 2011||Cardiac Pacemakers, Inc.||Monitoring lung fluid status using the cardiac component of a thoracic impedance-indicating signal|
|US8121693||Oct 23, 2008||Feb 21, 2012||Cardiac Pacemakers, Inc.||Baroreflex stimulation to treat acute myocardial infarction|
|US8126560||Dec 24, 2003||Feb 28, 2012||Cardiac Pacemakers, Inc.||Stimulation lead for stimulating the baroreceptors in the pulmonary artery|
|US8126561||Nov 5, 2009||Feb 28, 2012||Cardiac Pacemakers, Inc.||Implantable and rechargeable neural stimulator|
|US8131373||Mar 30, 2010||Mar 6, 2012||Cardiac Pacemakers, Inc.||Baroreflex stimulation synchronized to circadian rhythm|
|US8241221||Feb 5, 2009||Aug 14, 2012||Pacesetter, Inc.||Systems and methods for use with an implantable medical device for detecting stroke based on electrocardiac signals|
|US8442640||Jan 4, 2010||May 14, 2013||Cardiac Pacemakers, Inc.||Neural stimulation modulation based on monitored cardiovascular parameter|
|US8467864||Mar 11, 2010||Jun 18, 2013||Pacesetter, Inc.||Systems and methods for use by an implantable medical device for detecting and discriminating stroke and cardiac ischemia using electrocardiac signals and hemodynamic parameters|
|US8473076||Sep 6, 2011||Jun 25, 2013||Cardiac Pacemakers, Inc.||Lead for stimulating the baroreceptors in the pulmonary artery|
|US8571655||Jan 26, 2010||Oct 29, 2013||Cardiac Pacemakers, Inc.||Multi-site ventricular pacing therapy with parasympathetic stimulation|
|US8634921||Feb 22, 2012||Jan 21, 2014||Cardiac Pacemakers, Inc.||Implantable and rechargeable neural stimulator|
|US8649860 *||May 17, 2010||Feb 11, 2014||Cardiac Pacemakers, Inc.||Adaptive event storage in implantable device|
|US8660647||Jul 28, 2005||Feb 25, 2014||Cyberonics, Inc.||Stimulating cranial nerve to treat pulmonary disorder|
|US8660648||Nov 15, 2012||Feb 25, 2014||Cardiac Pacemakers, Inc.||Implantable and rechargeable neural stimulator|
|US8688201 *||Apr 24, 2008||Apr 1, 2014||Medtronic, Inc.||System and method to monitor ejection time and QT interval to alert patients before syncopal events|
|US8758260||Sep 13, 2011||Jun 24, 2014||Cardiac Pacemakers, Inc.||Ischemia detection using a heart sound sensor|
|US8768461||Sep 6, 2011||Jul 1, 2014||Pacesetter, Inc.||Systems and methods for controlling paired pacing interpulse intervals to reduce contractility disequilibrium using an implantable medical device|
|US8805501||Jan 25, 2012||Aug 12, 2014||Cardiac Pacemakers, Inc.||Baroreflex stimulation to treat acute myocardial infarction|
|US8805513||Apr 23, 2013||Aug 12, 2014||Cardiac Pacemakers, Inc.||Neural stimulation modulation based on monitored cardiovascular parameter|
|US8818513||Mar 1, 2012||Aug 26, 2014||Cardiac Pacemakers, Inc.||Baroreflex stimulation synchronized to circadian rhythm|
|US8843197 *||Mar 16, 2011||Sep 23, 2014||Pacesetter, Inc.||Method and system to correct contractility based on non-heart failure factors|
|US8929990||Dec 15, 2010||Jan 6, 2015||Cardiac Pacemakers, Inc.||Transvascular neural stimulation device and method for treating hypertension|
|US8989852||Aug 10, 2011||Mar 24, 2015||Pacesetter, Inc.||Systems and methods for use by implantable medical devices for detecting and discriminating stroke and cardiac ischemia using electrocardiac signals|
|US9020595||May 19, 2010||Apr 28, 2015||Cardiac Pacemakers, Inc.||Baroreflex activation therapy with conditional shut off|
|US9101275||Feb 25, 2014||Aug 11, 2015||Cardiac Pacemakers, Inc.||Determining systolic time intervals using heart sounds|
|US20050131470 *||Nov 22, 2004||Jun 16, 2005||Luca Vitali||Monitoring the sympathico-vagal activity by analysis of endocardiac acceleration in an active implantable medical device|
|US20050149129 *||Dec 24, 2003||Jul 7, 2005||Imad Libbus||Baropacing and cardiac pacing to control output|
|US20050240233 *||Apr 12, 2005||Oct 27, 2005||Biotronik Gmbh & Co. Kg||Electrotherapy device|
|US20060189874 *||Dec 21, 2005||Aug 24, 2006||Ela Medical, S.A.||Apparatus for non-invasive diagnosis of vasovagal syncope in a patient|
|US20070027496 *||Jul 28, 2005||Feb 1, 2007||Cyberonics, Inc.||Stimulating cranial nerve to treat pulmonary disorder|
|US20070093875 *||Oct 24, 2005||Apr 26, 2007||Cardiac Pacemakers, Inc.||Implantable and rechargeable neural stimulator|
|US20090270748 *||Apr 24, 2008||Oct 29, 2009||Medtronic, Inc.||System and Method to Monitor Ejection Time and QT Interval to Alert Patients Before Syncopal Events|
|US20100305642 *||Dec 2, 2010||Yanting Dong||Adaptive event storage in implantable device|
|US20120239104 *||Mar 16, 2011||Sep 20, 2012||Pacesetter, Inc.||Method and system to correct contractility based on non-heart failure factors|
|EP2364639A1||Feb 17, 2011||Sep 14, 2011||Pacesetter, Inc.||System for use with an implantable medical device for detecting and discriminating stroke and cardiac ischemia using electrocardiac signals and hemodynamic parameters|
|WO2009131865A1 *||Apr 14, 2009||Oct 29, 2009||Medtronic, Inc.||A system to monitor ejection time and qt interval to alert patients before syncopal events|
|Apr 24, 2002||AS||Assignment|
Owner name: PACESETTER, INC., CALIFORNIA
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PARK, EULJOON;KADISH, ALAN H.;FALKENBERG, ERIC;REEL/FRAME:012847/0716;SIGNING DATES FROM 20020306 TO 20020316
|Jul 15, 2002||AS||Assignment|
Owner name: PACESETTER, INC., CALIFORNIA
Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE EXECUTION DATE ON A PREVIOUSLY RECORDED DOCUMENT ON REEL 012847 FRAME 0716;ASSIGNORS:PARK, EULJOON;KADISH, ALAN H., M.D.;FALKENBERG, ERIC;REEL/FRAME:013093/0465;SIGNING DATES FROM 20020306 TO 20020314
|Mar 7, 2008||FPAY||Fee payment|
Year of fee payment: 4
|Mar 7, 2012||FPAY||Fee payment|
Year of fee payment: 8